Telix Pharmaceuticals has announced it will highlight new studies set to be presented at the European Association of Nuclear Medicine congress to be held from 9 to 13 September in Vienna.
Specifically, new data will be presented in on oral session on 10 September from the company's phase III trial evaluating the sensitivity and specificity of zirconium 89 (Zr-89) TLX250 PET/CT to detect clear cell renal cell cancer (ccRCC) in adult patients with indeterminate renal masses, Telix said.
In addition, the following Telix initiatives will also be presented:
- A phase III study of the company's TLX591 investigational prostate cancer therapy
- A session covering AI segmentation and primary characterization of prostate cancer lesions using models trained on gallium 68 (Ga-68) PSMA-11 PET/CT image datasets
- The Nobody Left Behind (NOBLE) Registry of Telix's SPECT-based prostate cancer imaging agent TLX599-CDx
- A preclinical evaluation of carbonic anhydrase IX (CAIX)-targeted lutetium-177 radionuclide therapy in combination with immune checkpoint inhibition
